Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug in Systemic Lupus Erythematosus
NCT07011043Phase 1Recruiting
- Sponsor
- Climb Bio
- Start
- Jul 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of budoprutug in systemic lupus erythematosus (SLE) (4 cohorts), sponsored by Climb Bio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 24 weeks, Incidence of Clinical Laboratory Abnormalities at 24 weeks and 9 more. Started Jul 2025; status: recruiting.
02
Drugs
budoprutug
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07011043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011043.